On demand: COVID-19 and its implications for thrombosis and anticoagulation

The puzzling pathogenesis behind COVID-19 has thrown up many clinical dilemmas for physicians across the globe, including haematologists. The rapid accumulation of evidence indicates the presence of a hypercoagulable state...

The puzzling pathogenesis behind COVID-19 has thrown up many clinical...

Blood cancers

The changing landscape in Australia of up-front treatment for multiple myeloma

The outlook for the management of multiple myeloma looks promising as new treatments, including combination therapy options, become more widely available in Australia. Join Professor Miles Prince and an expert panel from...

The outlook for the management of multiple myeloma looks promising as...

Blood cancers

Checkpoint inhibitors may sensitise patients with refractory NHL to improve responses

Checkpoint inhibitors may help sensitise relapsed/refractory non-Hodgkin lymphoma (NHL) to subsequent chemotherapy, according to US researchers. The retrospective study analysed data from 59 patients who received checkpoint blockade as a second or later line therapy between 2012 and 2017 and...

Checkpoint inhibitors may help sensitise relapsed/refractory non-Hodgkin lymphoma (NHL) to subsequent chemotherapy, according to US researchers. The retrospective study analysed...

Clotting disorders

Rivaroxaban cardioprotection outweighs bleeding risk: COMPASS re-analysis

The cardioprotective effect of rivaroxaban combined with low dose aspirin greatly outweighs the bleeding risk, especially in high-risk patients, a new analysis of the landmark COMPASS study shows. In 2017 the rivaroxaban trial in people with stable cardiovascular disease was stopped...

The cardioprotective effect of rivaroxaban combined with low dose aspirin greatly outweighs the bleeding risk, especially in high-risk patients, a...